| Literature DB >> 32516598 |
Alejandro Álvarez-Quilón1, Jessica L Wojtaszek2, Marie-Claude Mathieu3, Tejas Patel2, C Denise Appel2, Nicole Hustedt1, Silvia Emma Rossi1, Bret D Wallace2, Dheva Setiaputra1, Salomé Adam1, Yota Ohashi1, Henrique Melo1, Tiffany Cho4, Christian Gervais5, Ivan M Muñoz6, Eric Grazzini5, Jordan T F Young3, John Rouse6, Michael Zinda3, R Scott Williams7, Daniel Durocher8.
Abstract
The APEX2 gene encodes APE2, a nuclease related to APE1, the apurinic/apyrimidinic endonuclease acting in base excision repair. Loss of APE2 is lethal in cells with mutated BRCA1 or BRCA2, making APE2 a prime target for homologous recombination-defective cancers. However, because the function of APE2 in DNA repair is poorly understood, it is unclear why BRCA-deficient cells require APE2 for viability. Here we present the genetic interaction profiles of APE2, APE1, and TDP1 deficiency coupled to biochemical and structural dissection of APE2. We conclude that the main role of APE2 is to reverse blocked 3' DNA ends, problematic lesions that preclude DNA synthesis. Our work also suggests that TOP1 processing of genomic ribonucleotides is the main source of 3'-blocking lesions relevant to APEX2-BRCA1/2 synthetic lethality. The exquisite sensitivity of BRCA-deficient cells to 3' blocks indicates that they represent a tractable vulnerability in homologous recombination-deficient tumor cells.Entities:
Keywords: APE2; APEX2; BRCA1; BRCA2; RNASEH2; TDP1; TOP1; ribonucleotide; synthetic lethality
Mesh:
Substances:
Year: 2020 PMID: 32516598 PMCID: PMC7340272 DOI: 10.1016/j.molcel.2020.05.021
Source DB: PubMed Journal: Mol Cell ISSN: 1097-2765 Impact factor: 17.970